Article Information
- Received July 16, 2012
- Revision received February 15, 2013
- Accepted March 20, 2013
- First published May 1, 2013.
- Version of record published May 1, 2013.
Author Information
- Daniel Fleck1,
- Frauke van Bebber2,
- Alessio Colombo2,5,
- Chiara Galante1,
- Benjamin M. Schwenk2,
- Linnea Rabe1,
- Heike Hampel1,
- Bozidar Novak1,
- Elisabeth Kremmer3,
- Sabina Tahirovic2,
- Dieter Edbauer1,2,4,
- Stefan F. Lichtenthaler2,4,5,
- Bettina Schmid2,4,
- Michael Willem1, and
- Christian Haass1,2,4
- 1Adolf-Butenandt-Institute, Biochemistry, Ludwig-Maximilians-University, 80336 Munich,
- 2German Center for Neurodegenerative Diseases (DZNE), 80336 Munich, Germany,
- 3Institute of Molecular Immunology, Helmholtz Center Munich, 81377 Munich, Germany,
- 4Munich Cluster for Systems Neurology (SyNergy), 80336 Munich, Germany, and
- 5Neuroproteomics, Technical University of Munich, 81377 Munich, Germany
Author contributions
Author contributions: S.T., D.E., S.F.L., B.S., M.W., and C.H. designed research; D.F., F.v.B., A.C., C.G., B.M.S., L.R., H.H., B.N., and M.W. performed research; E.K. contributed unpublished reagents/analytic tools; D.F. and C.H. analyzed data; D.F., F.v.B., and C.H. wrote the paper.
Disclosures
- Received July 16, 2012.
- Revision received February 15, 2013.
- Accepted March 20, 2013.
This work was supported by the Deutsche Forschungsgemeinschaft Collaborative Research Center (Grant #SFB596 “Molecular Mechanisms of Neurodegeneration” A9 to M.W. and C.H., A16 to B.S., and Z2 to E.K.), the European Research Council under the European Union's Seventh Framework Programme (FP7/2007–2013)/ ERC Grant Agreement No. 321366-Amyloid (advanced grant to C.H.), the Helmholtz Young Investigator program (to D.E.), the Hans and Ilse Breuer Foundation (fellowship to D.F.), the Federal Ministry of Education and Research (“IG Alzheimer” to M.W. and C.H., Competence Network for Neurodegenerative Diseases (KNDD) to S.F.L. and C.H.). We thank Dr. Boris Schmidt (Technical University of Darmstadt) for kindly providing the inhibitor GI254023X, Dr. Paul Saftig (University Kiel) and Galderma for kindly providing the inhibitor GL 506-3, and Drs. Ignasi Forné, Lars Israel, and Axel Imhof (Center for Protein Analysis, Ludwig-Maximilians-University, Munich) for support with the MS analysis.
The authors declare no competing financial interests.
- Correspondence should be addressed to either Christian Haass or Michael Willem, Adolf-Butenandt-Institute, Biochemistry, Ludwig-Maximilians-University, Schillerstrasse 44, 80336 Munich, Germany, christian.haass{at}dzne.lmu.de or michael.willem{at}med.uni-muenchen.de
Online Impact